| アブストラクト | OBJECTIVE: Optimal management of multiple myeloma (MM) remains challenging, particularly among patients with transplant-ineligible newly diagnosed MM (TIE NDMM). Daratumumab + lenalidomide + dexamethasone (DRd) is approved in Japan for the treatment of TIE NDMM. A previously reported real-world, retrospective study of claims from the Japanese Medical Data Vision (MDV) database reported that first-line (1 L) DRd may improve outcomes versus second-line or later treatment in patients with TIE NDMM. METHODS: Data from this study underwent further analysis to investigate the correlation between 1 L DRd duration of treatment (DoT) and overall survival (OS). DoT and OS outcomes were also assessed in subgroups defined by age (<75, >/=75 to <80, >/=80 years) and Charlson Comorbidity Index (CCI; low [score 0], medium [1 or 2], high [3 or 4] or very high [>/=5]). RESULTS: Of 35,581 patients in the MDV database with a diagnosis of MM between January 1, 2016 and October 31, 2023, 200 patients (median age 77 years, median time from MM diagnosis 16 days) were prescribed 1 L DRd and had baseline/demographic data available at the start of treatment. After a median follow-up of 12.8 months, 1 L DRd DoT (median 26.9 months) showed high-positive correlation with OS (not reached) using Pearson's (r = 0.832), Spearman's rank (r(s)=0.777), Kendall's Tau (tau(b)=0.703), and Fleischer's (Corr [DoT, OS] = 0.789) coefficients in the overall population, and moderate- or high-positive correlation with OS across age and CCI score subgroups. CONCLUSION: These findings suggest that 1 L DRd DoT is a potential predictor of OS when used in Japanese clinical practice. |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| Pubmed追加日 | 2025/11/26 |
|---|
| 投稿者 | Suzuki, Kazuhito; Ito, Miku; Sakai, Chika; Tsuchiya, Hiroaki; Wu, David Bin-Chia; Koroki, Yosuke |
|---|
| 組織名 | Division of Clinical Oncology and Hematology, Department of Internal Medicine,;The Jikei University School of Medicine, Tokyo, Japan.;Medical Affairs, Johnson & Johnson, Tokyo, Japan.;Market Access Asia Pacific, Johnson & Johnson, Singapore, Singapore.;Saw Swee Hock School of Public Health, National University of Singapore,;Singapore, Singapore.;School of Pharmacy, Faculty of Health & Medical Sciences, Taylor's University;Malaysia, Subang Jaya, Malaysia. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41292503/ |
|---|
